Skip to main content
Premium Trial:

Request an Annual Quote

Caris Life Sciences Gets ISO 15189 Accreditation for Lab

NEW YORK (GenomeWeb News) – Caris Life Sciences today said that its tumor profiling lab in Phoenix, Ariz., has received ISO 15189 accreditation.

The accreditation was provided by the American Association for Laboratory Accreditation. The ISO 15189 standard covers qualifications and ongoing competency of the company's laboratory personnel, laboratory accommodation, equipment, reagents and supplies, pre-analytical and analytical factors, quality assurance considerations, and post-analytical factors, said Irving, Texas-based Caris.

The lab performs genomic testing associated with Caris Molecular Intelligence, the firm's tumor profiling service, which provides therapeutic guidance for up to 43 drug associations, "far exceeding the 12 that can be identified using next-generation sequencing alone," the firm said in a statement.

In addition to the ISO 15189 accreditation, the firm's lab also has a CLIA license, licenses from individual states including New York, and its biorepository has earned College of American Pathologists accreditation.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.